No way found to predict PML cases with MS drug Tysabri
This article was originally published in Scrip
There is no way to predict which MS patients receiving Biogen Idec/Elan's monoclonal antibody, Tysabri (natalizumab),will develop progressive multifocal leucoencephalopathy (PML), the potentially-fatal rare brain infection that has been associated with the therapy, according to a recent analysis conducted by Biogen Idec.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.